Therapeutic protein formulations comprising anti-DNABII antibodies and uses thereof

A stable aqueous therapeutic protein formulation comprising:

• (i) one or more therapeutic proteins, wherein the one or more therapeutic proteins comprise one or more anti-DNABII antibodies in an amount ranging from 10 to 150 mg/mL, wherein at least one anti-DNABII antibody is selected from the group consisting of
• (a) the heavy and the light chain of a first antibody comprises:
• the TRL 1068 heavy chain CDR sequences HCDR1/HCDR2/HCDR3 (SEQ ID NO:
• 1) and the TRL 1068 light chain CDR sequences LCDR1/LCDR2/LCDR3 (SEQ ID NO:
• 4), and/or
• (b) wherein the one or more anti-DNABII antibodies binds to the same epitope as the antibody of (a) and comprises a heavy and a light chain, wherein the heavy chain comprises:
• a polypeptide having at least 90% sequence identity with the TRL1068 heavy chain CDR sequences HCDR1/HCDR2/HCDR3 (SEQ ID NO:
• 1) and the light chain comprises a polypeptide having at least 90% identity with the TRL1068 light chain CDR sequences LCDR1/LCDR2/LCDR3 (SEQ ID NO:
• 4);
• and/or
• (c) the heavy and the light chain of a second antibody comprises:
• the TRL1330 heavy chain CDR sequences HCDR1/HCDR2/HCDR3 (SEQ ID NO:
• 2) and the TRL1330 light chain CDR sequences LCDR1/LCDR2/LCDR3 (SEQ ID NO:
• 5);
• (d) wherein the one or more anti-DNABII antibodies binds to the same epitope as the antibody of (c) and comprises a heavy and a light chain, wherein the heavy chain comprises:
• a polypeptide having at least 90% sequence identity with the TRL1330 heavy chain CDR sequences HCDR1/HCDR2/HCDR3 (SEQ ID NO:
• 2) and the light chain comprises a polypeptide having at least 90% identity with TRL1330 light chain CDR sequences LCDR1/LCDR2/LCDR3 (SEQ ID NO:
• 5)
• (e) the heavy and the light chain of a third antibody comprise:
• the TRL1337 heavy chain CDR sequences, HCDR1/HCDR2/HCDR3 (SEQ ID NO:
• 3) and the TRL 1337 light chain CDR sequences (LCDR1/LCDR2/LCDR3 of SEQ ID NO:
• 6), and
• (f) wherein the one or more anti-DNABII antibodies binds to the same epitope as the antibody of (e) and comprises a heavy and a light chain, wherein the heavy chain comprises:
• a polypeptide having at least 90% sequence identity with the TRL 1337 heavy chain CDR sequences, HCDR1/HCDR2/HCDR3 (SEQ ID NO:
• 3) and the light chain comprises a polypeptide having at least 90% identity with LCDR1/LCDR2/LCDR3 (SEQ ID NO:
• 6);
• (ii) histidine buffer,
• (iii) NaCl,
• (iv) an aqueous carrier, and (v) a surfactant,
• wherein a pH of the aqueous therapeutic formulation ranges from 5.5-8.0, and wherein the formulation is formulated for respiratory tract delivery and produces particles comprising the one or more therapeutic proteins upon aerosolization.